Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Dive into Tech Investments – A Comprehensive Guide

Shares of Bio-Techne Corp have moved 0.4% today, and are now trading at a price of $52.1. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 155,987 compared to the stock's average volume of 2,406,783.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. Based in Minneapolis, United States the company has 3,100 full time employees and a market cap of $8,167,560,704. Bio-Techne Corp currently offers its equity investors a dividend that yields 0.6% per year.

The company is now trading -22.56% away from its average analyst target price of $67.28 per share. The 13 analysts following the stock have set target prices ranging from $51.0 to $90.0, and on average give Bio-Techne Corp a rating of buy.

Over the last 12 months TECH shares have declined by -27.7%, which represents a difference of -38.9% when compared to the S&P 500. The stock's 52 week high is $83.62 per share and its 52 week low is $46.01. Based on Bio-Techne Corp's average net margin growth of 1.8% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2024 1,159,060 168,105 15 -40.0
2023 1,136,702 285,263 25 0.0
2022 1,105,599 272,051 25 66.67
2021 931,032 140,410 15 -51.61
2020 738,691 229,296 31 138.46
2019 714,006 96,072 13
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS